BFC
ADPT icon

Bedel Financial Consulting’s Adaptive Biotechnologies ADPT Stock Holding History

Bedel Financial Consulting’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-350
Closed -$5K – 205
2022
Q1 		$5K Sell
350
-100
-22% -$1.57K ﹤0.01% 755
2021
Q4 		$13K Buy
450
+300
+200% +$9.2K ﹤0.01% 641
2021
Q3 		$5K Buy
+150
New +$5.42K ﹤0.01% 764

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return

Bedel Financial Consulting's ADPT Position: Q2 2022 in Review

Bedel Financial Consulting sold out of Adaptive Biotechnologies (ADPT) in Q2 2022, closing a stake of 350 shares — an estimated $5K sold.

Bedel Financial Consulting first reported a position in ADPT in Q3 2021 and held it in 3 quarters. The position peaked at $13K in Q4 2021. 209 funds tracked by Wall St. Rank hold ADPT as of Q2 2022.

  • Bedel Financial Consulting reported no remaining Adaptive Biotechnologies position as of Q2 2022 after selling out during the quarter.
  • Bedel Financial Consulting sold 350 Adaptive Biotechnologies shares in Q2 2022, an estimated $5K.
  • Bedel Financial Consulting first reported a position in Adaptive Biotechnologies in Q3 2021 and held it in 3 quarters.
  • Bedel Financial Consulting's Adaptive Biotechnologies position peaked at $13K in Q4 2021.
  • 209 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2022.

Based on Bedel Financial Consulting's 13F filing for Q2 2022, filed 4 Aug 2022.